First Patient Enrolled in the US Phase 2 Combination Therapy of Akeso’s Ligufalimab with Azacitidine for Myelodysplastic Syndrome

Posted on by

HONG KONG, Aug. 6, 2024 /PRNewswire/ — Akeso has announced the completion of the first patient enrollment in the US for the phase II clinical trial of its innovative CD47 monoclonal antibody, ligufalimab (AK117), in combination with azacitidine for patients with newly diagnosed…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.